Leland Gershell
Stock Analyst at Oppenheimer
(4.55)
# 246
Out of 5,124 analysts
151
Total ratings
50%
Success rate
32.04%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiates: Outperform | $283 | $72.40 | +290.88% | 1 | Dec 23, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Outperform | $35 | $12.65 | +176.68% | 1 | Dec 23, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $22 → $54 | $24.72 | +118.45% | 6 | Dec 8, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $11.45 | +109.70% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $9.55 | +245.55% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $18 | $7.01 | +156.78% | 6 | Nov 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $29.25 | +23.08% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $45.28 | +92.14% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $24.37 | +228.27% | 1 | Sep 3, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $41.53 | +164.87% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $68.05 | -10.36% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $328.16 | +49.32% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $7.16 | +179.33% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $103.61 | +6.17% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $222.15 | +0.83% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $21.35 | +45.20% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $5.44 | +83.82% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $811.45 | -12.75% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $0.14 | +7,089.07% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $58.13 | +68.59% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $50.75 | +2.46% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $190.44 | -22.81% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.34 | +2,036.75% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $27.05 | +95.93% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.17 | +187.77% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $2.22 | +225,125.23% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $6.65 | +275.94% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $0.60 | +3,232.78% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $24.44 | +18.66% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $14.19 | +146.65% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.32 | +3,024.02% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.72 | +2,697.20% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.76 | +638.64% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.56 | +3,270.79% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.29 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $34.69 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.92 | +5,307.16% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $14.75 | - | 5 | Mar 31, 2020 |
Spruce Biosciences
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $72.40
Upside: +290.88%
Aardvark Therapeutics
Dec 23, 2025
Initiates: Outperform
Price Target: $35
Current: $12.65
Upside: +176.68%
Capricor Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $24.72
Upside: +118.45%
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $11.45
Upside: +109.70%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $9.55
Upside: +245.55%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $7.01
Upside: +156.78%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $29.25
Upside: +23.08%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $45.28
Upside: +92.14%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $24.37
Upside: +228.27%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $41.53
Upside: +164.87%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $68.05
Upside: -10.36%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $328.16
Upside: +49.32%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $7.16
Upside: +179.33%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $103.61
Upside: +6.17%
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $222.15
Upside: +0.83%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $21.35
Upside: +45.20%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $5.44
Upside: +83.82%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $811.45
Upside: -12.75%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $0.14
Upside: +7,089.07%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $58.13
Upside: +68.59%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $50.75
Upside: +2.46%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $190.44
Upside: -22.81%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.34
Upside: +2,036.75%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $27.05
Upside: +95.93%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.17
Upside: +187.77%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $2.22
Upside: +225,125.23%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $6.65
Upside: +275.94%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $0.60
Upside: +3,232.78%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $24.44
Upside: +18.66%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $14.19
Upside: +146.65%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.32
Upside: +3,024.02%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.72
Upside: +2,697.20%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.76
Upside: +638.64%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.56
Upside: +3,270.79%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.29
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $34.69
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $0.92
Upside: +5,307.16%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $14.75
Upside: -